Skip to search formSkip to main contentSkip to account menu

CGP 74588

Known as: CGP-74588, CGP74588 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2009
Highly Cited
2009
Platelet-derived growth factor (PDGF) and its receptors (PDGFR) are frequently coexpressed in meningiomas, potentially… 
Highly Cited
2008
Highly Cited
2008
Imatinib at 400 mg daily is standard treatment for chronic myeloid leukemia in chronic phase. We here describe the correlation of… 
Highly Cited
2008
Highly Cited
2008
Purpose: The aim of this study was to explore the effect of several demographic, biological, and pharmacogenetic covariates on… 
Highly Cited
2007
Highly Cited
2007
Purpose: To evaluate the effects of ritonavir, a potent inhibitor of CYP3A4, on the steady-state pharmacokinetics of imatinib… 
Highly Cited
2007
Highly Cited
2007
Imatinib, a protein tyrosine kinase inhibitor, may prevent the growth of glioblastoma cells. Unfortunately, its brain… 
Highly Cited
2005
Highly Cited
2005
Imatinib mesylate (GLEEVEC, GLIVEC, formerly STI571) has demonstrated unprecedented efficacy as first-line therapy for treatment… 
Highly Cited
2004
Highly Cited
2004
The study under discussion was a drug–drug interaction study in which the effect of ketoconazole, a potent CYP450 3A4 inhibitor… 
Highly Cited
2003
Highly Cited
2003
ObjectiveThis study was carried out to investigate the influence of CYP3A induction with rifampicin on imatinib (Gleevec… 
Highly Cited
2003
Highly Cited
2003
Despite the remarkable clinical response rates to imatinib in the treatment of bcr-abl leukemic patients, pharmacokinetic data on… 
Highly Cited
2003
Highly Cited
2003
PurposeImatinib (Glivec) has been established as a highly effective therapy for chronic myeloid leukemia and gastrointestinal…